SK Biopharmaceutical’s Xcopri (cenobamate) met the bar in a phase 3 trial that could support the company’s ambitions of building a blockbuster with an expansion into another seizures subtype. Now, ...
(RTTNews) - SK bioscience announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, 'GBP410' also known as SP0202, evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results